Investment Thesis
IN8BIO is a pre-revenue biotech company with no current commercial products, generating -$5.1M in annual losses while burning $4.9M in operating cash flow. While the company maintains strong liquidity ($21.9M cash) and a debt-free balance sheet providing approximately 4-5 years of runway, the absence of revenue, negative returns (ROE -22.3%, ROA -19.4%), and lack of insider confidence (zero Form 4 filings) indicate substantial execution and clinical development risk.
Strengths
- Strong liquidity position with $21.9M in cash (83% of total assets)
- Extremely healthy current ratio of 10.50x indicating short-term financial stability
- Clean balance sheet with zero debt and manageable liabilities ($3.5M)
Risks
- Zero revenue generation indicating no commercial viability yet
- Negative shareholder returns (ROE -22.3%, ROA -19.4%) signaling value destruction
- Annual cash burn of $4.9M limits runway to approximately 4-5 years without additional funding
- Pre-clinical/early-stage biotech with uncertain timeline to profitability
- Absence of insider buying activity (0 Form 4 filings) suggests limited insider confidence
- Significant execution risk dependent on successful drug development and regulatory approval
Key Metrics to Watch
- Time to first revenue generation and commercial product launch
- Cash burn rate and remaining cash runway
- Clinical trial progress and regulatory milestones for pipeline candidates
Financial Metrics
Revenue
N/A
Net Income
-5.1M
EPS (Diluted)
$-0.26
Free Cash Flow
-4.9M
Total Assets
26.3M
Cash
21.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-22.3%
ROA
-19.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
10.50x
Quick Ratio
10.50x
Debt/Equity
0.00x
Debt/Assets
13.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T10:42:40.078974 |
Data as of: 2026-03-31 |
Powered by Claude AI